EYES stock will probably rise if the company backs off of he sale of 60% to Pixium Vision By Mark R. Hake, CFA Mar 26, 2021, 12:08 pm EST Second Sight (NASDAQ: EYES) agreed to issue new shares that would give 60% control to its competitor in France, Pixium Vision, on Jan. 6. Since then, EYES stock has risen.
Full Answer
What is the price of eyes stock?
Since then, EYES stock has decreased by 52.7% and is now trading at $1.67. View which stocks have been most impacted by COVID-19. Are investors shorting Second Sight Medical Products?
How many shares of eyes stock were traded on Friday morning?
To put that in perspective, the stock’s daily average trading volume is about 2 million shares. EYES stock was up 179.2% as of Friday morning. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.
When did eyes raise $32 million in an IPO?
(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.
Why is second sight stock soaring higher after FDA approval?
Second Sight (NASDAQ:EYES) stock is soaring higher Friday after announcing approval from the U.S. Food and Drug Administration (FDA) for its Argus 2s Retinal Prosthesis System. Source: Shutterstock Second Sight notes that the Argus 2s Retinal Prosthesis System is a redesigned version of external hardware used alongside its Argus II implant.
Is EYES stock a good buy?
The consensus among 1 Wall Street analyst covering (NASDAQ: EYES) stock is to Strong Buy EYES stock.
Will Second Sight Medical stock go up?
Second Sight Medical Products Inc quote is equal to 2.125 USD at 2022-06-20. Based on our forecasts, a long-term increase is expected, the "EYES" stock price prognosis for 2027-06-11 is 4.681 USD. With a 5-year investment, the revenue is expected to be around +120.26%.
What happened Second Sight Medical?
Second Sight began phasing out the Argus II in 2019, a process that quickly ramped up first because of dire financial issues that nearly wiped out the entire company, and then, just this month, because of a plan to shift gears and merge with drug delivery implant maker Nano Precision Medical.
Is Second Sight still in business?
Medical products company Second Sight discontinued its Argus II retinal implants in 2019, IEEE Spectrum reported in an article published Tuesday. The implants mimic the function of the eye's photoreceptors with the help of special glasses and a video processing unit (VPU) that is worn around the waist.
Will bionic eyes exist?
In the United States, the FDA has approved just one commercially available bionic eye system. The device, called the Argus II Retinal Prosthesis System, was developed by a California-based company called Second Sight Medical Products.
How much will a bionic eye cost?
The device costs about $150,000 and restores minimal vision. Only 15 centers in the U.S. offer the technology, and with competition abroad, Second Sight is hoping its new brain implant could be used by far more pople.
How has Second Sight Medical Products' stock performed in 2022?
Second Sight Medical Products' stock was trading at $1.63 at the beginning of 2022. Since then, EYES stock has increased by 36.2% and is now tradin...
When is Second Sight Medical Products' next earnings date?
Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Monday, June 27th 2022. View our earnings foreca...
How were Second Sight Medical Products' earnings last quarter?
Second Sight Medical Products, Inc. (NASDAQ:EYES) released its earnings results on Monday, March, 28th. The medical device company reported ($0.02)...
Who are Second Sight Medical Products' key executives?
Second Sight Medical Products' management team includes the following people: Mr. Scott Dunbar , Acting Chief Exec. Officer (Age 64, Pay $301.39...
What is Will McGuire's approval rating as Second Sight Medical Products' CEO?
5 employees have rated Second Sight Medical Products CEO Will McGuire on Glassdoor.com . Will McGuire has an approval rating of 57% among Second S...
Who are some of Second Sight Medical Products' key competitors?
Some companies that are related to Second Sight Medical Products include Zynex (ZYXI) , Edap Tms (EDAP) , Semler Scientific (SMLR) , Stereotaxi...
What other stocks do shareholders of Second Sight Medical Products own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerb...
When did Second Sight Medical Products IPO?
(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per sh...
What is Second Sight Medical Products' stock symbol?
Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."